Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002-Reference-Cited by-同舟云学术

Elitek™–rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002

Published:2003-03 Issue:3 Volume:17 Page:499-514
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Navolanic P M,Pui C-H,Larson R A,Bishop M R,Pearce T E,Cairo M S,Goldman S C,Jeha S C,Shanholtz C B,Leonard J P,McCubrey J A

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/2402847.pdf

Reference53 articles.

1. Pocheldy C . Hyperuricemia in leukemia and lymphoma. NY State J Med 1973; 73: 1085–1092.

2. Labovitz ED . Hyperuricemia and the kidney in the hematologic patient. In: Jepson J (ed). Hematologic Problems in Renal Disease. Menlo Park: Addison-Wesley, 1979, pp. 293–306.

3. Cohen LF, Balow JE, Magrath IT, Poplack DG, Ziegler JL . Acute tumor lysis syndrome: a review of 37 patients with Burkitt's lymphoma. Am J Med 1980; 68: 486–491.

4. Hande KR, Hixson CV, Chabner BA . Postchemotherapy purine excretion in lymphoma patients receiving allopurinol. J Cancer Res 1981; 41: 2273–2279.

5. Tsokos GC, Balow JE, Spiegel RJ, Magrath IT . Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine 1981; 60: 218–229.

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumour lysis syndrome;Nature Reviews Disease Primers;2024-08-22

2. Rasburicase in treating tumor lysis syndrome: An umbrella review;Cancer Pathogenesis and Therapy;2023-07

3. Pharmacogenomics in Drug Metabolism Enzymes and Transporters;Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays;2023

4. Application and Development of Immunoinformatics Prediction in Therapeutic Protein Research;Pharmacy Information;2023

5. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype;Clinical Pharmacology & Therapeutics;2022-09-24